Teva Pharmaceutical Industries (TEVA) Research & Development (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Research & Development for 18 consecutive years, with $970.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 48.32% year-over-year to $970.0 million; the trailing twelve-month figure through Jun 2026 stood at $3.1 billion (up 20.49% YoY), and the FY2025 full-year result was $2.7 billion, up 5.71% from the prior year.
• Research & Development advanced to $970.0 million in Q2 2026 per TEVA's latest filing, from $696.0 million in the prior quarter.
• Across five years, Research & Development topped out at $970.0 million in Q2 2026 and bottomed at $539.0 million in Q3 2022.
• Historically, Research & Development has averaged $638.4 million across 5 years, with a median of $616.0 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Research & Development slipped 13.0% in 2022, then soared 48.32% in 2026.
• Over 5 years, Research & Development stood at $549.0 million in 2022, then advanced by 11.11% to $610.0 million in 2023, then rose by 6.56% to $650.0 million in 2024, then gained by 15.85% to $753.0 million in 2025, then rose by 28.82% to $970.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $970.0 million, $696.0 million, and $753.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.